Publications

Publications

The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs?

By:
Contributors: Hans Vogel Research Group
Metabolites. 2013 May 17;3(2):373-96. doi: 10.3390/metabo3020373.

Abstract

There has been a recent shift in how cancers are defined, where tumors are no longer simply classified by their tissue origin, but also by their molecular characteristics. Furthermore, personalized medicine has become a popular term and it could start to play an important role in future medical care. However, today, a “one size fits all” approach is still the most common form of cancer treatment. In this mini-review paper, we report on the role of nuclear magnetic resonance (NMR) metabolomics in drug development and in personalized medicine. NMR spectroscopy has successfully been used to evaluate current and potential therapies, both single-agents and combination therapies, to analyze toxicology, optimal dose, resistance, sensitivity, and biological mechanisms. It can also provide biological insight on tumor subtypes and their different responses to drugs, and indicate which patients are most likely to experience off-target effects and predict characteristics for treatment efficacy. Identifying pre-treatment metabolic profiles that correlate to these events could significantly improve how we view and treat tumors. We also briefly discuss several targeted cancer drugs that have been studied by metabolomics. We conclude that NMR technology provides a key platform in metabolomics that is well-positioned to play a crucial role in realizing the ultimate goal of better tailored cancer medicine.

 

PubMed

Download PDF

 

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks

We are excited to announce the recent online publication of PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks in the Journal of Clinical Oncology-Clinical Cancer Informatics!

PROSPeCT is a user-friendly online clinical information system that offers an easy and efficient way to obtain relevant and accurate information about patients from APCaRIs robust and expanding database. If you use PROSPeCT already then please cite this article in your work. If you do not use PROSPeCT yet then read this article for more details about easy-to-use and powerful query tool! Thank you to the Alberta Cancer Foundation, plus others, for supporting this project.

Citation
PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks
Maria Cutumisu, Catalina Vasquez, Maxwell Uhlich, Perrin H. Beatty, Homeira Hamayeli-Mehrabani, Rume Djebah, Albert Murtha, Russell Greiner, and John D. Lewis
JCO Clinical Cancer Informatics 2019 :3, 1-12 DOI: 10.1200/CCI.18.00144

2019.05 Cutumisu et al PROSPeCT JCO CCI

- Unknown